QS-21 STIMULON™ Adjuvant

About Agenus

Agenus is focused on developing novel immunotherapies designed to overcome the limitations of first-generation checkpoint inhibitors, particularly in 'cold' or immunologically resistant tumors. The company's most advanced asset, the BOT/BAL combination, has shown promising activity in multiple solid tumors and is now entering registrational studies. With a 30-year legacy in immunotherapy, Agenus leverages a multi-faceted platform to create treatments that aim to deliver deeper and more durable responses for cancer patients.

Therapeutic Areas